New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access Is Easy. Choosing the Right ETF Is Not

With 1,790 launches through July 2026, finding an ETF is easy and choosing one is not. 46% of share classes hold under $50 million, and nearly 7 in 10 allocators are reassessing their holdings, with portfolio fit the top criterion. See how 620 professionals select ETFs.

›ETF Issuers›Invesco›SBIO

SBIO

Invesco NASDAQ Biotech UCITS ETF

Passive ETF Equity

The SBIO Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: NASDAQ Biotechnology Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). The dividend policy is capitalization.

$73.39

+$1.9 (+2.66%) today

7:00 AM 10/15/26 Closed

1D price range

$71.54$73.48

52W price range

$52.99$77.12

YTD Perf.

+20.52%

YTD Flows

Annualized volatility

Fund AuM

€498M

Share class AuM

€498M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE00BQ70R696

TER

0.4%

Inception date

11/7/2014

Issuer

Invesco

Benchmark

NASDAQ Biotechnology Index

Replication method

Dividend policy

Capitalization

Compare similar ETFs

ETF Name	1w perf.
SXLV State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF	+2.95%
XLVS Invesco Health Care S&P US Select Sector UCITS ETF	+2.95%
UMDV iShares US Medical Devices UCITS ETF	+3.52%
IUHE iShares S&P 500 Health Care Sector UCITS ETF	+2.98%
ZUH BMO Equal Weight U.S. Health Care Index ETF	+1.85%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	-0.15%
203780 Mirae Asset TIGER NASDAQ BIO ETF	-1.55%
453640 SAMSUNG Kodex S&P500 Health Care ETF	+1.39%
CURE Global X S&P Biotech ETF	-2.29%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	-0.22%
185680 Samsung KODEX SYNTH-US Biotech ETF	-2.93%
WELL Harbor Health Care UCITS ETF	-1.03%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	-0.10%
ZXLV.F BMO SPDR Health Care Select Sector Index ETF	+3.02%
ZHU BMO Equal Weight US Health Care Index ETF	+1.72%

API

PerformanceDec 31, 2025 - Oct 14, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

99.70%

Unavailable

0.29%

Latest SBIO news

No content available for this fund

FAQ about SBIO

SBIO is a Passive ETF. This ETF provides exposure to US Equities.

SBIO tracks the NASDAQ Biotechnology Total Return Index - USD, through a unfunded swap replication method.

SBIO carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.

SBIO was introduced to the market on November 7, 2014. It trades on Ireland, among other exchanges

Invesco NASDAQ Biotech UCITS ETF, SBIO, is provided by Invesco. Learn more about Invesco here.

SBIO oversees €498M in assets as of October 14, 2026.

SBIO follows a capitalizing, meaning it reinvests income within the fund.

As of August 31, 2026, SBIO has significant geographic allocations in USA, Netherlands and United Kingdom.

As of August 31, 2026, SBIO focuses largely on Healthcare.

As of August 31, 2026, SBIO holds 250 positions in its portfolio, with 52.23% of assets concentrated in its top 15 holdings.

As of August 31, 2026, SBIO top three holdings include Amgen, Inc., Vertex Pharmaceuticals, Inc. and Gilead Sciences, Inc..

The base currency of SBIO is USD.

Top 10 holdings

Data as of 08/31/26

Amgen, Inc.

8.66%

Vertex Pharmaceuticals, Inc.

8.26%

Gilead Sciences, Inc.

7.39%

Regeneron Pharmaceuticals, Inc.

5.33%

Moderna, Inc.

3.60%

Revolution Medicines, Inc.

2.83%

Illumina, Inc.

2.09%

Alnylam Pharmaceuticals, Inc.

2.08%

Biogen, Inc.

2.07%

argenx SE

1.84%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Access Is Easy. Choosing the Right ETF Is Not

Invesco NASDAQ Biotech UCITS ETF

FAQ about SBIO

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US